The Itch that Rashes

Annapolis, MD February 9, 2004-—According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 20% of infants and young children will suffer from atopic dermatitis (AD), a chronic, recurring skin condition. Skin is sensitive, dry and itchy. Scratching causes the skin to develop a red, scaly rash that can eventually lead to thickened, brownish areas on the skin. This is why atopic dermatitis is often called the "itch that rashes" rather than the "rash that itches." The itching of the skin may be most severe at night.

Most children with AD develop the symptoms before age 5. More than half of these children continue to have some AD symptoms as adults. Ten to twenty percent of doctor referrals to dermatologists are AD-related.

The cause of AD is unknown; a combination of heredity and environment is suspected. AD usually occurs in children who have a family history of allergic conditions including allergic rhinitis (hay fever), urticaria (hives), or asthma. In addition, AD is more prevalent in urban areas and dryer climates.

In the absence of a cure for AD, treatment is focused on reducing symptoms, and controlling the severity and recurrence of attacks. Patients are educated to avoid potential allergens and maintain the moisture of their skin. Flare-ups of AD can be treated with creams and ointments, coal tar, light or ultraviolet light therapy, and oral medications. Leukotriene inhibitors, such as Singulair®, normally prescribed for asthma, are often used for AD as well. Medications that suppress or control the immune response are also prescribed.
Not all treatments work for all people, so new treatments are continually sought. All investigational medications undergo rigorous testing before clinical research trials are available for human volunteers.

Clinical Research Associates® is conducting clinical research studies to further evaluate the safety and effectiveness of an investigational topical medication for treating the signs and symptoms of atopic dermatitis. Patients in 45 cities throughout the US, Canada, and Mexico can volunteer for this clinical trial. Potential study participants must have been diagnosed with, or be experiencing symptoms of, atopic dermatitis. Qualified participants will receive study-related exams, lab tests, and study medication. Parents or legal guardians may call 1-800-59-STUDY for additional information.

For media information and to arrange an interview, please contact the COMMUNITY OUTREACH NETWORK® via e-mail at outreach@clinicaltrials.com or call (800) 664-5099.




This article courtesy of http://www.doyouhavemesothelioma.com.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.

Did you find what you are looking for? If NOT.. Try google.

Submit Your Article